Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Coherus Bio (CHRS)

Coherus Bio (CHRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 83,296
  • Shares Outstanding, K 115,209
  • Annual Sales, $ 257,240 K
  • Annual Income, $ -237,890 K
  • EBIT $ -164 M
  • EBITDA $ -160 M
  • 60-Month Beta 0.69
  • Price/Sales 0.33
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.68
  • Most Recent Earnings $-0.14 on 08/08/24
  • Next Earnings Date 11/06/24 [AMC]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 357.32% ( +35.11%)
  • Historical Volatility 51.94%
  • IV Percentile 98%
  • IV Rank 62.56%
  • IV High 567.48% on 06/05/24
  • IV Low 6.15% on 08/15/24
  • Put/Call Vol Ratio 0.18
  • Today's Volume 267
  • Volume Avg (30-Day) 379
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 19,362
  • Open Int (30-Day) 17,551

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.20
  • Number of Estimates 2
  • High Estimate -0.19
  • Low Estimate -0.20
  • Prior Year -0.38
  • Growth Rate Est. (year over year) +47.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6699 +0.01%
on 11/04/24
1.1200 -40.18%
on 10/07/24
-0.3700 (-35.58%)
since 10/04/24
3-Month
0.6699 +0.01%
on 11/04/24
1.5600 -57.05%
on 08/15/24
-0.6800 (-50.37%)
since 08/02/24
52-Week
0.6699 +0.01%
on 11/04/24
3.7300 -82.04%
on 11/06/23
-2.9400 (-81.44%)
since 11/03/23

Most Recent Stories

More News
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

CHRS : 0.6700 (-7.33%)
Coherus BioSciences: Q2 Earnings Snapshot

Coherus BioSciences: Q2 Earnings Snapshot

CHRS : 0.6700 (-7.33%)
Coherus BioSciences: Q1 Earnings Snapshot

Coherus BioSciences: Q1 Earnings Snapshot

CHRS : 0.6700 (-7.33%)
Why Coherus Biosciences Stock Tumbled on Thursday

The company fell well short of expectations for its fourth quarter.

CHRS : 0.6700 (-7.33%)
Coherus BioSciences: Q4 Earnings Snapshot

Coherus BioSciences: Q4 Earnings Snapshot

CHRS : 0.6700 (-7.33%)
Why Coherus BioSciences Stock Jumped Today

As promised, Coherus is using the proceeds of a recent divestiture to pay down debt and reduce interest expenses.

CHRS : 0.6700 (-7.33%)
Why Coherus BioSciences Stock Is Sinking Today

The positive reaction to Coherus' sale of its ophthalmology franchise to Sandoz didn't last long.

CHRS : 0.6700 (-7.33%)
Why Coherus Biosciences Popped Today

Coherus is divesting its non-core ophthalmology franchise.

SDZNY : 46.7100 (+1.46%)
CHRS : 0.6700 (-7.33%)
Why Coherus BioSciences Stock Jumped Today

Coherus finally received FDA approval for its Udenyca OnBody injector system.

CHRS : 0.6700 (-7.33%)
Cytokinetics, New York Times rise; Iovance Biotherapeutics fall, Wednesday, 12/27/2023

Stocks that are trading heavily or have substantial price changes on Wednesday: Cytokinetics, New York Times rise; Iovance Biotherapeutics fall

CYTK : 51.48 (-0.66%)
NEM : 45.76 (+1.10%)
TMUS : 224.25 (+0.43%)
FCX : 46.27 (+1.49%)
TM : 172.70 (-0.08%)
CHRS : 0.6700 (-7.33%)
NYT : 52.45 (-7.71%)

Business Summary

Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid...

See More

Key Turning Points

3rd Resistance Point 0.7996
2nd Resistance Point 0.7737
1st Resistance Point 0.7218
Last Price 0.6700
1st Support Level 0.6440
2nd Support Level 0.6181
3rd Support Level 0.5662

See More

52-Week High 3.7300
Fibonacci 61.8% 2.5610
Fibonacci 50% 2.1999
Fibonacci 38.2% 1.8389
Last Price 0.6700
52-Week Low 0.6699

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar